公开(公告)号：WO1993019624A1

公开(公告)日：1993-10-14

申请号：PCT/US1993001124

申请日：1993-02-09

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  DEMICHELE, Stephen, Joseph ,  GREGORY, Timothy, James

IPC: A23L01/303

CPC classification number: A23L33/16 ,  A23L33/12 ,  A23L33/40 ,  Y10S426/80 ,  Y10S426/801 ,  Y10S514/904

Abstract: A liquid nutritional product for enteral feeding contains a fat source which provides desirable effects when fed to pulmonary patients. The fat source provides a ratio, by weight, of n-6 to n-3 fatty acids in the range of about 1.5 to about 3.0, a ratio of Linoleic acid (18:2n6) to Alpha-Linolenic acid (18:3n3) in the range of about 3.0 to about 10.0, and a ratio of the sum of Eicosapentaenoic acid (20:5n3) and Docosahexaenoic acid (22:6n3) to Gamma-Linolenic acid (18:3n6) in the range of about 1.0 to about 10.0. In a preferred embodiment the nutritional product contains quantities of nutrients having antioxidant properties in vivo, such as beta-carotene, vitamin E, vitamin C, selenium, and taurine.

公开(公告)号：WO1993018067A1

公开(公告)日：1993-09-16

申请号：PCT/US1993002011

申请日：1993-03-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  KUNDU, Samar ,  LA FLEUR, Marie, Anne

IPC: C07K15/28

CPC classification number: C07K16/18 ,  G01N33/92 ,  G01N2800/044

Abstract: The present invention relates to a method for directly measuring concentrations of cholesterol associated with specific lipoproteins in a plasma sample. The method involves the specific capture of intact lipoprotein particles containing cholesterol from a plasma sample with a specific lipoprotein binding agent. The quantity of the specific lipoprotein cholesterol present in the sample is then measured by detecting the amount of binding-agent-lipoprotein complexes that have formed in the reaction. The cholesterol contained in the binding-agent-lipoprotein complexes can be detected by reacting the complexes with labeled cholesterol specific binding agents and measuring the amount of label bound thereto, or by releasing the cholesterol in the complexes and measuring the amount of cholesterol released. The specific lipoprotein binding agent can be bound to a solid support. The assay method may also incorporate a further step of separating the solid support from the sample before detecting the presence of cholesterol bound to the solid support.

Abstract translation: 本发明涉及直接测定血浆样品中与特定脂蛋白相关的胆固醇浓度的方法。 该方法包括用特异性脂蛋白结合剂特异性捕获含有来自血浆样品的胆固醇的完整脂蛋白颗粒。 然后通过检测在反应中形成的结合剂 - 脂蛋白复合物的量来测量样品中存在的特定脂蛋白胆固醇的量。 包含在结合剂 - 脂蛋白复合物中的胆固醇可以通过使复合物与标记的胆固醇特异性结合剂反应并测量与其结合的标记量或通过释放复合物中的胆固醇并测量释放的胆固醇的量来检测。 特异性脂蛋白结合剂可以结合固体支持物。 测定方法还可以包括在检测结合到固体支持物的胆固醇的存在之前从样品中分离固体支持物的另外的步骤。

公开(公告)号：WO1993017681A1

公开(公告)日：1993-09-16

申请号：PCT/US1993001594

申请日：1993-02-24

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  WINN, Martin ,  DE, Biswanath ,  ZYDOWSKY, Thomas, M. ,  KERKMAN, Daniel, J. ,  DeBERNARDIS, John, F. ,  ROSENBERG, Saul, H. ,  SHIOSAKI, Kazumi ,  BASHA, Fatima, Z. ,  SPINA, Kenneth, P. ,  VON GELDERN, Thomas, W. ,  BOYD, Steven ,  YAMAMOTO, Diane, M. ,  FUNG, Anthony, K., L.

IPC: A61K31/41

CPC classification number: C07D403/12 ,  C07D413/10 ,  C07D417/12

Abstract: Compounds are disclosed having formula (I) wherein D, E, G, L, M, A, R'1, L', and M' are defined herein. The compounds of the invention are angiotensin II receptor antagonists.

Abstract translation: 公开了具有式（I）的化合物，其中D，E，G，L，M，A，R'1，L'和M'在本文中定义。 本发明的化合物是血管紧张素II受体拮抗剂。

公开(公告)号：WO1993017585A1

公开(公告)日：1993-09-16

申请号：PCT/US1993001117

申请日：1993-02-08

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BORSCHEL, Marlene, Wynn ,  CHURELLA, Helen, Rezabek ,  YAO, Benita, Co ,  KEDZIERSKI, Bogdan, Kazimierz

IPC: A23L01/304

CPC classification number: A23L33/16 ,  Y10S426/806

Abstract: Selenium is provided in a nutritional product by incorporating selenate into a premix with an iron (II) and/or copper (II) salt which is water soluble and then combining the premix with a source of nutrition to form a nutritional product.

公开(公告)号：WO1993016384A1

公开(公告)日：1993-08-19

申请号：PCT/US1993000917

申请日：1993-02-03

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  VON BEHRENS, Wieland, E. ,  HAIFLICH, Sherry ,  GLAZIER, John ,  ROCHE, John, W. ,  DIRECTOR, Bruce, A.

IPC: G01N33/48

CPC classification number: G01N33/5094 ,  G01N15/1434 ,  G01N15/1459 ,  G01N2015/1006 ,  G01N2015/1402 ,  G01N2015/1413 ,  G01N2015/1477 ,  Y10T436/107497

Abstract: A method for identifying, characterizing, categorizing and enumerating cells. The method is based on the survival of different cell populations in the sample when the sample condition is being changed to elicit a response. The cells are being monitored either by direct disappearance of intact cells or by the appearance of cell structures, carcasses, ghosts or residuum. In one embodiment, a leukocyte cell decay rate in the presence of an erythrolytic agent is determined by monitoring leukocyte counts at several time intervals. The decay rate is used to determine the presence of fragile leukocyte and the number of leukocytes in the sample. The method corrects errors in leukocyte counts which enables the use of strong erythrolytic agents in presence of lyse-resistant erythrocytes. The leukocyte decay rate can be back extrapolated to time zero to provide an accurate estimate of the leukocyte count initially present in the sample.

Abstract translation: 用于识别，表征，分类和枚举单元格的方法。 该方法基于当样品条件改变以引发响应时​​样品中不同细胞群体的存活。 正在通过完整细胞的直接消失或细胞结构，尸体，鬼魂或残渣的出现来监测细胞。 在一个实施方案中，通过以几个时间间隔监测白细胞计数来确定在存在红细胞分解剂的情况下的白细胞细胞衰变速率。 衰减率用于确定样品中易碎白细胞的存在和白细胞数。 该方法校正白细胞计数中的错误，这使得在溶血性红细胞存在下使用强烈的红血球药物。 白细胞衰减速率可以反向外推到时间零，以提供样品中最初存在的白细胞计数的准确估计。

公开(公告)号：WO1993015097A1

公开(公告)日：1993-08-05

申请号：PCT/US1993000988

申请日：1993-01-28

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  POPE, Mark, R. ,  BIENIARZ, Christopher

IPC: C07H15/24

CPC classification number: C07H15/24 ,  C12Q1/34 ,  C12Q2334/00 ,  G01N2333/924 ,  Y10S436/80 ,  Y10S436/808

Abstract: Novel pyrene-trisulfonate derivatives and the use thereof in a method for the determination of glycohydrolitic enzyme activity are provided. The method comprises the steps of (a) forming a test solution comprising a test sample containing the glycohydrolitic enzyme and a pyrene-trisulfonate derivative of the present invention, wherein the derivative is hydrolyzed by the glycohydrolytic enzyme to result in the formation of free 8-hydroxy-1,3,6-pyrene trisulfonate as a function of, and which can be correlated to, the amount of the glycohydrolytic enzyme present in the test sample, and (b) measuring and correlating either the intensity of fluorescence, or the optical density, of the test solution to the presence or amount of the glycohydrolytic enzyme in the test sample. A preferred pyrene-trisulfonate derivative is pyrene-(1,3,6-trisulfonic acid)-8-β-D-glucuronide for the determination of β-D-glucuronidase for the diagnosis of periodontal disease.

公开(公告)号：WO1993014225A1

公开(公告)日：1993-07-22

申请号：PCT/US1993000295

申请日：1993-01-13

Applicant: ABBOTT LABORATORIES ,  ZELDIS, Jerome, B.

Inventor： ABBOTT LABORATORIES ,  HENRARD, Denis, R. ,  NIMMS, Larry, T.

IPC: C12Q01/68

CPC classification number: C12Q1/703 ,  C12Q1/6804 ,  G01N33/56988

Abstract: A direct method for detecting viral nucleic acid of HIV-1 in a biological sample suspected of containing the target nucleic acid by adsorption of the biological sample onto a solid support coupled to an anti-HIV-1 envelope antibody, followed by amplification of the target nucleic acid sequence and detection of the amplified product. Amplification methods which can be used include the polymerase chain reaction and the ligase chain reaction.

Abstract translation: 通过将生物样品吸附到与抗HIV-1包膜抗体偶联的固体支持物上，在怀疑含有靶核酸的生物样品中检测HIV-1的病毒核酸的直接方法，随后扩增靶 核酸序列和扩增产物的检测。 可以使用的扩增方法包括聚合酶链反应和连接酶链反应。

公开(公告)号：WO1993014199A1

公开(公告)日：1993-07-22

申请号：PCT/US1993000146

申请日：1993-01-08

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MARCOTTE, Patrick, A.

IPC: C12N09/48

CPC classification number: C12N9/6462 ,  A61K38/00 ,  C12Y304/21073

Abstract: The present invention provides a method of making low molecular weight urokinase-type plasminogen activator comprising cleaving high molecular weight urokinase-type plasminogen activator with the metalloproteinase pump-1. Pharmaceutical compositions and methods of thrombolysis or preventing blood clot formation using that low molecular weight urokinase-type plasminogen activator are also provided.

Abstract translation: 本发明提供一种制备低分子量尿激酶型纤溶酶原激活物的方法，其包括用金属蛋白酶泵-1切割高分子量尿激酶型纤溶酶原激活物。 还提供了使用该低分子量尿激酶型纤溶酶原激活剂溶栓或预防血块形成的药物组合物和方法。

公开(公告)号：WO1993013780A1

公开(公告)日：1993-07-22

申请号：PCT/US1993000468

申请日：1993-01-19

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LARTEY, Paul, A. ,  NELLANS, Hugh, N. ,  KLEIN, Larry, L. ,  FAGHIH, Ramin

IPC: A61K31/70

CPC classification number: C07H17/08

Abstract: 4''-Deoxy derivatives of erythromycin having formula (I) and pharmaceutically acceptable salts thereof, which are enhancers of gastric motility but have minimal antibacterial activity, as well as pharmaceutical compositions containing the same and methods for their use and preparation.

Abstract translation: 4' - 具有式（I）的红霉素的脱氧衍生物及其药学上可接受的盐，其是胃动力的增强剂但具有最小的抗菌活性，以及​​含有其的药物组合物及其使用和制备方法。

公开(公告)号：WO1993012771A1

公开(公告)日：1993-07-08

申请号：PCT/US1992011011

申请日：1992-12-18

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MEYER, Glenn, A. ,  MAZER, Terrence, B.

IPC: A61K09/38

CPC classification number: A61K9/0095 ,  A61K9/5052

Abstract: Prolamine fractions of grain proteins, applied in weight ratios of 5 to 100 % relative to the active agent being coated, effectively prevent the partitioning of water-soluble or water-insoluble drugs at neutral pH's in the mouth and thereby mask the taste of orally-administered drugs, which normally have a bitter taste, without sacrificing bioavailability. Zein, gliadin or a mixture thereof, particularly in combination with between 2.5 and 15 % of water-insoluble vegetable source oil or wax capable of plasticizing the prolamine fraction, when applied to particles, granules, tablets or other forms of drugs or nutritionals, to an effective thickness of about 1 to about 35 micrometers, in order to encapsulate and prevent release of an orally-administered pharmaceutical or nutritional in a suspension or chewable dosage form until such medicament reaches the stomach.

Abstract translation: 颗粒蛋白质的相对于所涂覆的活性剂的重量比为5〜100％的颗粒蛋白质成分有效地防止了水溶性或水不溶性药物在口腔中性pH下的分配，从而掩盖口服的味道， 施用的药物，其通常具有苦味，而不牺牲生物利用度。 玉米蛋白，麦醇溶蛋白或其混合物，特别是当施用于颗粒，颗粒，片剂或其它形式的药物或营养物时，特别是与2.5至15％的水不溶性植物来源油或能够增塑醇溶蛋白成分的蜡相结合， 有效厚度为约1至约35微米，以便包封并防止口服药物或营养物在悬浮液或咀嚼剂型中的释放，直到该药物到达胃。